Biostatistics is a key component of biomedical research and is essential for the interpretation of study results. Statistical techniques inform, among others, about the experimental design, treatment plan, evaluation of a new versus a standard treatment, and identify prognostic factors. The Biostatistics Center provides statistical expertise to researchers and doctors on diverse topics from all areas of observational and experimental biomedical cancer research. This involves developing and implementing statistical approaches to cover a wide range of topics including the design and analysis of epidemiologic studies and clinical trials, the identification of prognostic and predictive biomarkers, sample size calculations, risk prediction, as well as animal and in vitro experiments. In the recent past, the Biostatistics Center has been involved in, among others, prediction of hearing loss after cisplatin-based chemoradiation in patients with locally advanced head-and-neck cancer, biomarker-based treatment of breast cancer with adjuvant tamoxifen, comparison of platforms for array comparative genomic hybridization (aCGH) to identify breast cancers with a BRCA-like copy number profile, and dysphagia and trismus after concomitant chemo-Intensity-Modulated Radiation Therapy (chemo-IMRT) in advanced head and neck cancer. Moreover, the Biostatistics Center is closely involved with several international epidemiological studies on cancer incidence and exposure to chemicals and radiation, and it offers the annual Basic Medical Statistics Course.